Thyroid stimulating immunoglobulin (TSI) is an antibody your immune system produces that mimics the hormone normally responsible for controlling your thyroid. Instead of your brain regulating how much thyroid hormone to make, TSI locks onto the same receptor on thyroid cells and forces them to overproduce, leading to hyperthyroidism. It is the primary driver behind Graves’ disease, the most common cause of an overactive thyroid.
How TSI Affects the Thyroid
Normally, your pituitary gland releases thyroid-stimulating hormone (TSH), which travels to the thyroid and binds to receptors on thyroid cells. This signals the gland to produce the right amount of thyroid hormones. When levels are sufficient, the pituitary dials TSH back down. It’s a feedback loop that keeps your metabolism steady.
TSI short-circuits that loop. Because it binds to the exact same receptor as TSH, the thyroid can’t tell the difference. But unlike TSH, TSI doesn’t respond to feedback signals. It keeps stimulating the thyroid regardless of how much hormone is already circulating. The result is continuous, unregulated production of thyroid hormones, which causes the thyroid to enlarge (goiter) and pushes the body into a hyperthyroid state.
TSI vs. TRAb: What’s the Difference?
If you’ve seen “TRAb” on a lab report alongside TSI, it helps to understand the relationship. TRAb stands for TSH-receptor antibodies, and it’s an umbrella term for all antibodies that bind to the TSH receptor. There are several subtypes. Some stimulate the thyroid (these are TSI), some block it, and some have a neutral effect.
Standard TRAb tests measure the total amount of these receptor-binding antibodies without distinguishing which type they are. A TSI-specific test, by contrast, identifies only the stimulating antibodies, the ones actually responsible for driving Graves’ disease. This makes TSI a more precise marker. In clinical studies, TSI detected Graves’ disease with 98.8% sensitivity and 96.4% specificity when compared against a broad control group that included people with other thyroid conditions and healthy individuals.
Symptoms of Elevated TSI
Because TSI forces the thyroid to overproduce hormones, the symptoms mirror those of hyperthyroidism:
- Cardiovascular: fast or irregular heartbeat, palpitations
- Metabolic: weight loss despite normal or increased appetite, hot flashes, increased sweating
- Neurological: anxiety, irritability, trembling hands
- Musculoskeletal: muscle weakness (especially in the upper arms and thighs), decreased bone density from calcium loss
- Other: loose or frequent bowel movements, hair loss, nails separating from the nail bed, menstrual irregularities in women
TSI can also affect the eyes, a condition called Graves’ orbitopathy. The eyes may become more prominent, feel gritty or irritated, produce excess tears, or cause double vision. The eyelids may not close fully. Eye involvement doesn’t always track with how severe the hyperthyroidism is; some people develop significant eye symptoms even when their thyroid hormone levels are only mildly elevated.
What the TSI Test Is Used For
A TSI test is primarily ordered to confirm or rule out Graves’ disease when someone presents with hyperthyroidism. Several conditions can cause an overactive thyroid, including toxic nodules and thyroid inflammation, so identifying TSI narrows the diagnosis. When compared specifically against non-Graves’ causes of hyperthyroidism, TSI testing showed 97.7% sensitivity and 83.6% specificity, meaning it correctly identified the vast majority of Graves’ cases while ruling out most other causes.
Beyond initial diagnosis, TSI levels help in two other important situations: predicting relapse after treatment and monitoring risk during pregnancy.
Predicting Relapse After Treatment
Many people with Graves’ disease take antithyroid medications for a period (often 12 to 18 months) before stopping to see if the disease stays in remission. TSI levels at the time of stopping medication offer a meaningful signal about what comes next. In one study, patients with higher TSI activity at the time they stopped medication had a 40.3% relapse rate within five years, compared to 24.3% in those with lower levels. This predictive value was particularly strong in women. In practical terms, if your TSI remains elevated when your doctor is considering stopping medication, the odds of the disease returning are roughly doubled.
TSI During Pregnancy
TSI antibodies can cross the placenta, which means a pregnant person’s antibodies can stimulate the baby’s thyroid. This is a concern even for women whose own Graves’ disease is currently under control or who previously had their thyroid removed or treated with radioactive iodine, since the immune system can continue producing TSI regardless of whether the thyroid is still present.
TSI levels more than three times the upper normal limit during the second or third trimester are associated with increased risk of fetal thyrotoxicosis. Research has found the lowest maternal TSI level linked to neonatal thyrotoxicosis was 4.4 U/L, which was 3.7 times the upper limit of normal. Pregnant individuals with a history of Graves’ disease typically have their TSI monitored to assess whether the baby may need closer surveillance.
Understanding Your Lab Results
TSI results can be reported in different units depending on the lab and the type of assay used. One common automated test uses a cutoff of 0.55 IU/L, with values above that considered positive. Older tests report results as a percentage of baseline activity, where values above a certain threshold (often around 140%) indicate stimulating antibody activity. Because reference ranges vary by laboratory and testing method, the number alone doesn’t tell the full story without knowing which assay was used.
Two main types of tests exist. Binding immunoassays detect whether antibodies attach to the TSH receptor but can’t distinguish stimulating antibodies from blocking ones. Newer bridge-based immunoassays are more specific for TSI, though still not perfect. Cell-based bioassays go a step further by measuring whether the antibodies actually stimulate thyroid cell activity in a lab dish, giving a functional readout rather than just detecting the antibody’s presence. Bioassays are considered the most informative but are less widely available.
If your TSI result is positive and you have symptoms of hyperthyroidism, it strongly points to Graves’ disease. A negative result, given the test’s very high negative predictive value (99.9% in one large evaluation), makes Graves’ disease extremely unlikely and suggests another cause for your symptoms. If your result is borderline or unexpected, the testing method matters, and your provider may consider repeating the test with a different assay type.